株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のB型肝炎ワクチン市場

Global Hepatitis B Vaccines Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 311601
出版日 ページ情報 英文 91 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
世界のB型肝炎ワクチン市場 Global Hepatitis B Vaccines Market 2014-2018
出版日: 2014年08月27日 ページ情報: 英文 91 Pages
概要

B型肝炎は炎症性疾患で、B型肝炎ウイルスによる感染症です。B型肝炎は、B型肝炎ワクチンの接種によって予防することができます。世界のB型肝炎ワクチン市場は、2013年〜2018年のCAGRで、4%の成長が見込まれています。

当レポートでは、世界のB型肝炎ワクチン市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 疾患の概要

  • B型肝炎:急性・慢性感染症
  • B型肝炎:地理的分布
  • B型肝炎:国の予防接種率の推計
  • 慢性B型肝炎の危険因子
  • B型肝炎:診断

第6章 イントロダクション

第7章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第8章 市場区分:構成別

  • 単剤ワクチン
  • 混合ワクチン

第9章 市場区分:エンドユーザー年齢層

  • 成人用ワクチン
  • 小児用ワクチン

第10章 地域区分

  • 南北アメリカ
  • 欧州・中東・アフリカ地域
  • アジア太平洋地域

第11章 購買基準

第12章 市場成長促進要因

第13章 促進要因とその影響

第14章 市場課題

第15章 促進要因と課題の影響

第16章 市場動向

第17章 動向とその影響

第18章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析
  • その他の有力ベンダー

第19章 後期パイプライン候補

  • 主要情報

第20章 主要ベンダー分析

  • 事業概要、事業区分、主要情報、SWOT分析など
    • GlaxoSmithKline
    • Merck
    • Sanofi Pasteur

第21章 関連レポート

図表

目次
Product Code: IRTNTR3995

About Hepatitis B Vaccines

Hepatitis B is an inflammatory condition that occurs due to infection by hepatitis B virus. Hepatitis B virus is an enveloped virus that belongs to the family of hepadnavirus. It contains a circular genome with partially double-stranded DNA. The virus interferes with the normal functioning of the liver cells. Following the viral infection, the immune system is activated against virus and hepatocytes infected with viruses. This, in turn, leads to the inflammation of the liver. Extra-hepatic manifestations of hepatitis B include polyarteritis nodosa, Gianotti-Crosti syndrome, transient serum sickness-like syndrome, and membranous glomerulonephritis. Perinatal transmission of hepatitis B virus is the most common mode of infection spread. Age of a person at the time of infection and infecting dose of virus are important factors that determine the severity of acute or chronic hepatitis B. Most of the patients suffering from acute hepatitis B recover spontaneously without significant consequences. The chronic form of infection, in some cases, can progress up to cirrhosis and liver cancer. Hepatitis B infection can be prevented by immunization with hepatitis B vaccines.

TechNavio's analysts forecast the Global Hepatitis B Vaccines market to grow at a CAGR of 4.00 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Hepatitis B Vaccines market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various vaccines intended for active immunization against different serogroups of hepatitis B virus. In terms of composition, the Global Hepatitis B Vaccines market can be segmented into the following: Mono Vaccines and Combination Vaccines.

TechNavio's report, the Global Hepatitis B Vaccines Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Hepatitis B Vaccines market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • GlaxoSmithKline
  • Merck
  • Sanofi Pasteur

Other Prominent Vendors

  • Dynavax Technologies
  • Janssen Pharmaceuticals
  • LG Life Sciences
  • Kaketsuken
  • Shenzhen Kangtai Biological Products

Market Driver

  • Increased Awareness about Hepatitis B Infection and Prevention

For a full, detailed list, view our report

Market Challenge

  • Inadequate Vaccine Coverage

For a full, detailed list, view our report

Market Trend

  • Combination Vaccines

For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Disease Overview

  • 05.1. Hepatitis B: Acute and Chronic Infection
  • 05.2. Hepatitis B: Geographical Distribution
  • 05.3. Hepatitis B: Estimated National Immunization Coverage
    • 05.3.1. Hepatitis B Birth Dose Vaccine
    • 05.3.2. Third Dose of Hepatitis B Vaccine
  • 05.4. Chronic Disease Prone Individuals for Hepatitis B
  • 05.5. Hepatitis B: Diagnosis
    • 05.5.1. Serological Markers
    • 05.5.2. Hepatitis B Serologic Test Interpretation

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Composition

  • 08.1. Mono Vaccines
  • 08.2. Combination Vaccines

09. Market Segmentation by End-user Age Group

  • 09.1. Global Adult Hepatitis B Vaccines Market
    • 09.1.1. Market Size and Forecast
    • 09.1.2. Geographical Segmentation
  • 09.2. Global Pediatric Hepatitis B Vaccines Market
    • 09.2.1. Market Size and Forecast

10. Geographical Segmentation

  • 10.1. Global Hepatitis B Vaccines Market in the Americas
    • 10.1.1. Market Size and Forecast
  • 10.2. Global Hepatitis B Vaccines Market in the EMEA Region
    • 10.2.1. Market Size and Forecast
  • 10.3. Global Hepatitis B Vaccines Market in the APAC Region
    • 10.3.1. Market Size and Forecast

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2013
    • 18.2.1. GlaxoSmithKline
    • 18.2.2. Sanofi Pasteur
    • 18.2.3. Merck
  • 18.3. Other Prominent Vendors and Future Players

19. Late-stage Pipeline Candidates

  • 19.1. Key Information for Late-stage Pipeline Candidates
    • 19.1.1. PR5I
    • 19.1.2. Heplisav-B

20. Key Vendor Analysis

  • 20.1. GlaxoSmithKline
    • 20.1.1. Key Facts
    • 20.1.2. Business Overview
    • 20.1.3. Business Segmentation
    • 20.1.4. Business Segmentation by Revenue 2012 and 2013
    • 20.1.5. Sales by Geography
    • 20.1.6. Pipeline Products
    • 20.1.7. Business Strategy
    • 20.1.8. Key Information
    • 20.1.9. SWOT Analysis
  • 20.2. Merck
    • 20.2.1. Key Facts
    • 20.2.2. Business Overview
    • 20.2.3. Business Segmentation by Revenue 2013
    • 20.2.4. Business Segmentation by Revenue 2012 and 2013
    • 20.2.5. Sales by Geography
    • 20.2.6. Business Strategy
    • 20.2.7. Key Developments
    • 20.2.8. SWOT Analysis
  • 20.3. Sanofi Pasteur
    • 20.3.1. Key Facts
    • 20.3.2. Business Overview
    • 20.3.3. Business Strategy
    • 20.3.4. Recent Developments
    • 20.3.5. SWOT Analysis

21. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Pathway of Hepatitis B Progression
  • Exhibit 3: Number of Hepatitis B Birth Doses Administered in WHO Regions
  • Exhibit 4: Trend of Hepatitis B Birth Doses Administered in WHO Regions 2000-2013
  • Exhibit 5: Percentage Share of Different Regions in 2013
  • Exhibit 6: Number of Third Doses of Hepatitis B Administered in WHO Regions
  • Exhibit 7: Trend of Third Doses of Hepatitis B Administered in WHO Regions 2000-2013
  • Exhibit 8: Percentage Share of Different Regions in 2013
  • Exhibit 9: Comparison of Third Dose and Birth Dose in 2013 in WHO Regions
  • Exhibit 10: Disease Progression of Hepatitis B
  • Exhibit 11: Significance of Serological Markers
  • Exhibit 12: Interpretation of Serological Markers
  • Exhibit 13: Global Hepatitis B Vaccines Market 2013-2018 (US$ million)
  • Exhibit 14: Global Hepatitis B Vaccines Market Segmentation by Composition
  • Exhibit 15: Dosage Regimen of Engerix-B
  • Exhibit 16: Dosage Regimen of Fendrix
  • Exhibit 17: Dosage Regimen of Recombivax HB
  • Exhibit 18: Dosage Regimen of Infanrix hexa
  • Exhibit 19: Dosage Regimen of Hexacima/Hexyon
  • Exhibit 20: Dosage Regimen of Twinrix
  • Exhibit 21: Dosage Regimen of Ambirix
  • Exhibit 22: Dosage Regimen of Comvax
  • Exhibit 23: Global Hepatitis B Vaccines Market Segmentation by End-user Age Group
  • Exhibit 24: Global Hepatitis B Vaccines Market Segmentation by End-user Age Group 2013
  • Exhibit 25: Global Hepatitis B Vaccines Market Segmentation by End-user Age Group 2013-2018 (US$ million)
  • Exhibit 26: Global Hepatitis B Vaccines Market Segmentation by End-user Age Group 2013-2018
  • Exhibit 27: Global Adult Hepatitis B Vaccines Market 2013-2018 (US$ million)
  • Exhibit 28: Global Adult Hepatitis B Vaccines Market by Geography Segmentation
  • Exhibit 29: Global Pediatric Hepatitis B Vaccines Market 2013-2018 (US$ million)
  • Exhibit 30: Global Hepatitis B Vaccines Market by Geographical Segmentation 2013
  • Exhibit 31: Global Hepatitis B Vaccines Market by Geographical Segmentation 2018
  • Exhibit 32: Global Hepatitis B Vaccines Market by Geographical Segmentation 2013-2018 (US$ million)
  • Exhibit 33: Global Hepatitis B Vaccines Market by Geographical Segmentation 2013-2018
  • Exhibit 34: Hepatitis B Vaccines Market in the Americas 2013-2018 (US$ million)
  • Exhibit 35: Hepatitis B Vaccines Market in the EMEA Region 2013-2018 (US$ million)
  • Exhibit 36: Hepatitis B Vaccines Market in the APAC Region 2013-2018 (US$ million)
  • Exhibit 37: Territories with Moderate to High Risk of Developing Hepatitis B Infection
  • Exhibit 38: Benefits of Combination Vaccines
  • Exhibit 39: GlaxoSmithKline plc: Business Segmentation 2013
  • Exhibit 40: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 41: GlaxoSmithKline plc: Sales by Geography 2013
  • Exhibit 42: GlaxoSmithKline plc: Pipeline Products 2013
  • Exhibit 43: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 44: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 45: Merck & Co. Inc.: Sales by Geography 2013
Back to Top